Awarded

Meningokokken-Impfstoff, tetravalent (A, C, W135, Y) Pulver u. Lösungsmittel zur Herstellung einer Injektionslsg. (ab 6 Wochen) St

Name: Meningokokken-Impfstoff, tetravalent (A, C, W135, Y) Pulver u. Lösungsmittel zur Herstellung einer Injektionslsg. (ab 6 Wochen) St
Creator: PBMG eG
Published: 2026-10-31
License: https://ted.europa.eu/en/simap/legal-notice

Original language: German

Track this recordWith Adjudera Pro, get alerted before a contract here runs out.

Buyer: PBMG eG
Winners: Pfizer Pharma GmbH
Contract value: no value published
Bids received: 1
Published: 31 Oct 2026
Awarded: 19 Oct 2026
Contract start: 1 Jul 2027
Contract end: 30 Jun 2028stated
Sector: Medical equipment and pharmaceuticals
Region: Hamburg
Source: Original notice on TED (763157-2026)

More awards from this buyer

Awarded	Buyer	Winner	Contract value	Published
Omalizumab 75 mg in 0.5 ml Lsg. Injektionslösung in einer Fertigspritze St	PBMG eG	Celltrion Healthcare	—	31 Oct 2026
Omalizumab 300 mg in 2 ml Lsg. Injektionslösung Fertigpen o. Fertigspritze St	PBMG eG	Celltrion Healthcare	—	31 Oct 2026
Omalizumab 150 mg in 1 ml Lsg. Injektionslösung in einer Fertigspritze St	PBMG eG	Celltrion Healthcare	—	31 Oct 2026
Urapidil 90 mg Retard-Kapseln St	PBMG eG	ALIUD PHARMA GmbH	—	31 Oct 2026
Formoterol hemifumarat-1-Wasser 12 μg Inhalationspulver (Novolizer, Cyclohaler, Turbohaler, Easyhaler) St	PBMG eG	ALIUD PHARMA GmbH	—	31 Oct 2026
Brinzolamid 10 mg, Timolol 5 mg in 1 ml Tropfen Augentropfen St a 5 ml	PBMG eG	Zentiva Pharma GmbH	—	31 Oct 2026